Evommune, Inc. (EVMN): Total Liabilities
$19.38M
As of 2025-12-31
$24.36M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.38M | -32.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $28.52M | n/a | 2026-03-05, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $57.01M | +28.3% |
Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗